Ifupinostat Hydrochloride is named as a drug or biological intervention in 3 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include BeBetter Med Inc (2) and Ruijin Hospital (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Relapsed/Refractory Diffuse Large B-Cell Lymphoma; Previously Untreated Peripheral T-Cell Lymphoma; Acute Lymphoblastic Leukemia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06792253 | Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Phase 3 | Recruiting |
| NCT07301138 | BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients (ClinicalTrials.gov ↗) Acute Lymphoblastic Leukemia |
Phase 2 | Not yet open |
| NCT07676175 | A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) (ClinicalTrials.gov ↗) Previously Untreated Peripheral T-Cell Lymphoma |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 1 |
| Previously Untreated Peripheral T-Cell Lymphoma | 1 |
| Acute Lymphoblastic Leukemia | 1 |
| Lead sponsor | Trials |
|---|---|
| BeBetter Med Inc | 2 |
| Ruijin Hospital | 1 |
| Register | Ifupinostat Hydrochloride trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ifupinostat Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ifupinostat Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.